The Value of Prognostic Grouping of Prostatic Carcinomas for Urologists and Pathologists

Urol Int. 2015;95(4):436-44. doi: 10.1159/000437170. Epub 2015 Sep 9.

Abstract

Objectives: To improve the prognostic stratification for different therapeutic options of prostatic carcinomas (PCa) with low and intermediate grade by combining Gleason grading with cytological findings and prognostic grade grouping.

Methods: We analyzed PCa after radical prostatectomy using the combined grading of Gleason and Helpap, which allows an exact differentiation particularly of low and intermediate grade tumors. Additionally, we attached time-interval and percentage value of recurrences of prostate-specific antigen (PSA) as well as death on disease (DoD) to the prognostic grade grouping.

Results: Carcinomas of group I/V are very low-grade tumors with very good prognosis without biochemical recurrence and DoD predestining for active surveillance (AS). The group II/V with low progress of PSA without DoD allows the options of an active treatment or AS and shows a prognostic separation of the intermediate group III/V. Within the high-grade groups, a differentiation is necessary between GS 7b (4 + 3), 8, and 9-10 regarding TNM staging and rate of DoD. Prognosis of GS 7b (4 + 3) group III/V is more favourable without DoD in contrast to group IV and V/V with cases of DoD.

Conclusion: Morphologically prognostic classification by using combined grading may improve the prognostic stratification of patients with PCa.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / blood
  • Biopsy
  • Disease-Free Survival
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Grading / methods*
  • Prognosis
  • Prostate / pathology*
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / diagnosis*
  • Retrospective Studies

Substances

  • Biomarkers, Tumor
  • Prostate-Specific Antigen